127 related articles for article (PubMed ID: 28883272)
1. [Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis].
Suzuki T; Kawamoto K; Tamura S; Uemura S; Kaihatsu A; Nemoto H; Kobayashi H; Ushiki T; Fuse K; Shibazaki Y; Moriyama M; Masuko M; Narita M; Sone H; Aoki S; Nakamura N; Oshima K; Takizawa J
Rinsho Ketsueki; 2017; 58(8):905-911. PubMed ID: 28883272
[TBL] [Abstract][Full Text] [Related]
2. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
5. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N; Kodama F; Tsuyama N; Sakata S; Takeuchi K; Ishibashi D; Koyama S; Ishii Y; Yamamoto W; Takasaki H; Hagihara M; Kuwabara H; Tanaka M; Hashimoto C; Yamazaki E; Koharazawa H; Fujimaki K; Sakai R; Fujisawa S; Ishigatsubo Y
Hematol Oncol; 2015 Mar; 33(1):9-14. PubMed ID: 24519501
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and survival of peripheral T-cell lymphoma-not otherwise specified: a report of 57 cases].
Chen X; Dong DF; Wu YY; Huang HY; Liang J; Li EX
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):916-9. PubMed ID: 20193331
[TBL] [Abstract][Full Text] [Related]
8. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of characteristics in 4 patients with primary gastric peripheral T-cell lymphoma-not otherwise specified].
Li YY; Yang S; Zhang LN; Fan L; Wang L; Zhang R; Xu J; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1374-7. PubMed ID: 23257436
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
Tolkachjov SN; Weenig RH; Comfere NI
J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
15. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
[TBL] [Abstract][Full Text] [Related]
16. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
17. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
[TBL] [Abstract][Full Text] [Related]
19. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Oluwasanjo A; Kartan S; Johnson W; Alpdogan O; Gru A; Mishra A; Haverkos BM; Gong J; Porcu P
Cancer Treat Res; 2019; 176():83-98. PubMed ID: 30596214
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
